43 results about "Normal aging" patented technology

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and / or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and / or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

Hypertension in mammalian patients, especially elderly human patients, derived from ingestion of NSAIDs or through the normal aging process is treated by administration to the patient of a vitamin B6 (or derivative) supplement. Where the patient requires the continued administration of an NSAID for pharmacological purposes, the NSAID is administered in conjunction with a vitamin B6 supplement. The invention further provides combination pharmaceutical combinations of an NSAID and a vitamin B6 supplement, e.g. orally administrable tablets or capsules, for use in treating such conditions.

The present invention relates to the enhancement of cognition in an individual by delivery of a histone acetylation regulator, such as a histone deacetylase inhibitor. The individual may have normal or poor memory, and the poor memory may be the result of a pathogenic condition or a non-pathogenic condition, such as with normal aging-related impairment. In a specific embodiment, enhancement of cognition occurs in an individual having a mental retardation syndrome.

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and / or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and / or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.

The invention provides a method for predicting life of transformer insulation and a management system thereof. The technical proposal of the method comprises the steps as follows: firstly essential data is input; subsequently, transformer winding hot-spot temperature theta i, the total working-hour number of each hot-spot temperature tau i, each temperature relative heat aging rate Vhi, main transformer insulation each temperature relative life loss Li and insulation accumulation relative life loss Lh are calculated step by step; then the design life Lo of a transformer under a normal aging state is confirmed; transformer insulation remaining aging life Hrl is calculated; and finally, a recommended maintenance treatment measure is obtained. A product provided by the invention is the life management system consisting of a calculation / application server and software, a database server, an external system interface, a transformer primary side current and environment temperature measuring instrument, a web page server and a client browser. The invention has the advantage of being capable of predicting the remaining life of the transformer insulation quantificationally during a using stage.

The invention provides a transformer health state analysis method which comprises the following steps: regarding a normal aging health state and an insulation operation health state of a transformer as health index analysis targets, and determining weight assignments of the two correspondingly; in the normal aging state, obtaining the health index of the transformer body; in the insulation operation state, selecting a plurality of index systems, obtaining the health index of each selected index system and the corresponding weight values according to a preset processing rule, and obtaining a new weight value of each selected index system according to the weight assignment of the insulation operation; and calculating the product of the weight assignment of the normal aging and the health index of the transformer body, and calculating the product of the health index of each index system selected under the insulation operation state and the corresponding new weight value, and regarding the sum value obtained by accumulating the plurality of calculated products as a comprehensive health index. The method can improve accuracy and reliability of health state assessment and defect diagnosis of the transformer, and provides information support and technological base guarantee for intelligent decision and analysis of a smart power grid.

The present invention provides methods for improving cognitive function, improving mood, and decreasing aggression in a normal adult subject, and in a subject having symptoms characteristic of a neurological disorder, by administration of a nutriceutical formulation of the invention to the subject. The invention additionally features methods of treating neurological disorders, depression, and aggression using nutriceutical formulations. Nutriceutical compositions and formulations for use in the methods of the invention, and kits containing nutriceutical compositions and formulations, are also provided.

The invention discloses a heat treatment technique for improving the aging post plasticity of cold forming Beta titanium alloy. The technique comprises the following steps of: carrying out short time aging at the normal aging temperature to Beta titanium alloy treated by solid solution and cold deformation, then properly improving the aging temperature for holding temperature for short time so as to eliminate deforming defects of dislocation remained by cold deformation and the like by a high-temperature restoring mechanical part, thus leading the plasticity of materials to be restored under the premise of guaranteeing the strength of alloy and shortening the aging time. The technique has simple operation and easy implementation and is suitable for batch processing in the industrial production process.

The invention provides a power transformer time-varying outage risk assessment method considering weather factors. The method comprises the following steps: S1, establishing a comprehensive meteorological risk index system influencing the operation state of the power transformer; S2, according to the aging failure probability and accidental failure probability of the power transformer, obtaining the comprehensive time-varying operation failure probability of the power transformer; S3,using synthetic meteorological risk index to modify the synthetic time-varying operation failure probability ofthe power transformer, and obtaining the time-varying outage risk assessment model of the power transformer considering weather factors. According to the power transformer time-varying outage risk assessment method of the present invention, the meteorological factors which have great influence on the stable operation of transformer are quantified, and the fault outage model of transformer considering normal aging and accidental fault is optimized by using the synthesized meteorological risk index, and the time-varying outage risk model considering weather factors is obtained to make the riskassessment of transformer more accurate.

A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4 / 5 and NT-3, into the EC. The method is useful in therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease or for normal aging.

A method to increase both the libido and sexual responsiveness in a mammalian female. The method comprises the steps of administering a compound having a combination of DHEA, Yohimbe and L-arginine to that female. When a woman's decreased or absent libido, currently referred to in the medical literature as hypoactive sexual desire, is believed in the gynecologic / urologic communities to be caused by a decreased "testosterone effect', such treatment may be beneficial. This decreased "testosterone effect' can be due to normal aging, contraceptive medications, anti-depressant medication, a lowered cholesterol diet or a decreased percentage of body fat as a result of a rigorous exercise regime. This present invention defines those three above-stated specific nutritional supplements with specific physiological effects well documented in the peer reviewed medical literature. This combination of nutritional supplements increases the testosterone effect in both the brain as well as in the clitoral tissues, to improve a woman's libido, without prescription testosterone preparations, or the uncertainties of non-medically proven herbal remedies.

The invention provides a method and a device for aging processing of a media access control (MAC) table entry. The method comprises the following steps of: forming an MAC table from at least two MAC entries of a service which are matched with each other; determining a reference aging MAC table entry according to the MAC table; and setting the reference aging MAC table entry to participate in the normal aging, and aging all MAC table entries in the MAC table when the reference aging MAC table entry is aged. Through the scheme, a plurality of MAC table entries which are matched with one another are simultaneously aged, so the service corresponding to the plurality of MAC table entries which are matched with one another is not interrupted.

The invention relates to a device for processing the neighbor discovery (ND) item of a router, which comprises a microcode transmission module, a transmission table management module and an ND protocol module, wherein the microcode transmission module is used for counting the used times of the ND item when transmitting a message through the neighbor discovery item; the transmission table management module is used for providing the count number of the ND item for the ND protocol module; the ND protocol module is used for reading and accumulating the count number of the ND item of each line card through the transmission table management module when the ND item is just changed into a stale state, and reading and accumulating the count number of the ND item of each line card again after the ND item is kept in the stale state for a specific time, wherein the accumulated results of the ND item read in two times are compared, and the ND item is aged and deleted if the accumulated results of the ND item read in two times are the same. Moreover, the invention further provides a method for processing the ND item of a router. Through the technical scheme of the invention, the normal aging for the ND item is ensured, and packet loss is avoided.

The invention relates to a PP2A agonist for preventing and treating mental disorders caused by normal aging or reduction of PP2A activity or expression. The inventor of the invention finds that MPH has a treatment effect on mental disorders of old zebrafish, old mice and ppp2r2cm / m mutant zebrafish, can eliminate DNA damaged and senile nerve cells of the old zebrafish, the old mice and the ppp2r2cm / m mutant zebrafish and improve PP2A activity, and further finds that the PP2A agonist can improve the mental disorders of the ppp2r2cm / m zebrafish, the old zebrafish and the old mice and eliminate DNA damaged and senile nerve cells of the old zebrafish, the old zebrafish and the old mice. On the basis, the invention provides an application of MPH and PP2A agonists to preparation of medicines for preventing and treating mental disorder caused by normal age increase or PP2A activity reduction.

The present invention relates to transposon activation and mobilization, particularly in the brain, during normal aging; reporter systems to detect such mobilization, along with cells and transgenic animals containing such systems; methods of monitoring neuronal function during normal aging; methods of determining the risk of age-related neuronal decline and age-related mortality; and the use of transposon inhibitors and apoptosis inhibitors to delay age-related neuronal decline and age-related mortality.

The invention discloses an LED aging device, and the device comprises a support. The support is provided with a multilayer installation frame, and the installation frame is provided with lamp holders which are arranged in rows. The lamp holders are connected with a testing power supply, and the support is provided with an air supply port and an air outlet. The air supply port and the air outlet are respectively disposed at two ends of the support. The air supply port is connected with a centrifugal fan through an air pipe. The air supply port and the air outlet are respectively disposed at two ends of the support, thereby enabling the air in the device to be able to circulate quickly, thereby enabling heat generated in the aging process of a large number of LED lamps to be dissipated quickly, enabling the air temperature of the interior of the device to remain normal, and guaranteeing the normal aging of the lamps.

The present invention relates to compounds of general formula I wherein R1, R2, R3 and R4 are as defined herein which maybe used for the treatment of schizophrenia, obsessive-compulsivepersonality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

The present invention relates to compounds of general formulawhereinAr1 / Ar2 are phenyl or a 5 or 6-membered heteroaryl;R1 / R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2;or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and / or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-.The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

The invention discloses a hydrogen atom frequency standard ionization bubble aging method. The problems that in the prior art, ionization bubbles take a long time to reach the normal aging brightnessis poor in batch consistency and uncontrollable in product development cycle are solved. The method comprises the following steps that an HF solution with the concentration being 25%-50% is injected into ionization bubbles, and ionization bubbles are placed in a water tank for 30 minutes to 1 hour; the HF solution in the ionization bubbles is washed with pure water; and the ionization bubbles is injected with absolute ethyl alcohol, and an operator waits for evaporation of the absolute ethyl alcohol. Through the hydrogen atom frequency standard ionization bubble aging method, the time requiredfor the ionization bubble to reach a normal working state can be effectively shortened and is shortened to less than two days from longer than a week, the batch aging success rate reaches 100%, raw materials are saved, the cost is reduced, the product quality and labor productivity are improved, and guarantee is provided for control over the hydrogen atom frequency standard development cycle.

Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal muscle, including age-related muscle dysfunction. In addition, the invention relates to therapeutic compositions comprising nucleotides and / or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorder, including those related to thr normal aging process. Moreover, the invention relates to the treatment and / or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced.

The present invention relates to compounds of general formula I wherein R1, R2 and R3 are as defined herein which may be used for the treatment of schizophrenia, obsessive-compulsivepersonality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4 / 5 and NT-3, into the EC. The method is useful in therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease or for normal aging.

The invention belongs to the field of coating and particularly relates to a high light-retaining and color-retaining acrylic acid modified polyurethane finishing coat and a preparation method thereof.The finishing coat contains a component A and a component B in a weight ratio of 100 to (20-30), wherein the component A contains the following raw materials in parts by weight: 40-50 parts of an acrylate emulsion, 50-60 parts of a polyurethane emulsion, 3-6 parts of an enhancer, 10-15 parts of pigments and fillers, 1-3 parts of a dispersing agent, 0.5-1 part of a defoaming agent, 0-5 parts of other aids and the balance of deionized water; and the component B is a water-based curing agent. The adopted enhancer contains a benzophenone structure with an excellent light stabilization effect andis cable of strongly absorbing ultraviolet light, so that the damage caused by the ultraviolet light to the finishing coat is avoided; and meanwhile, the enhancer has no possibility of being decomposed and decolorized, further contains an N-cyclohexyl p-methoxyaniline structure and has good ozone aging performance, radiation aging resistance and normal aging resistance, and the structure is not decolorized after being placed in air and sunlight for a long time, so that the finishing coat with high light-retaining and color-retaining properties is obtained.

The present invention relates to compounds of general formula Ior pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, R and n are as defined herein.The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.